Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes

• Published in: Medical science monitor. Basic research Vol. 20; pp. 112 - 117
• Main Authors: Komsuoglu Celikyurt, Ipek, Mutlu, Oguz, Ulak, Guner, Uyar, Emre, Bektaş, Emine, Yildiz Akar, Furuzan, Erden, Faruk, Tarkun, Ilhan
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 30.07.2014
• Subjects: Animal Studies; Animals; Anti-Anxiety Agents - pharmacology; Anti-Anxiety Agents - therapeutic use; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - physiopathology; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Diabetic Neuropathies - drug therapy; Diabetic Neuropathies - physiopathology; Disease Models, Animal; Immobilization; Male; Maze Learning - drug effects; Mice, Inbred BALB C; Motor Activity - drug effects; Peptides - pharmacology; Peptides - therapeutic use; Reaction Time - drug effects; Time Factors; Venoms - pharmacology; Venoms - therapeutic use
• ISSN: 2325-4416; 2325-4394; 2325-4416
• DOI: 10.12659/MSMBR.891168

Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model. Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested. Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model. Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.